Mechanistically, AR inhibits TDO2 transcription by binding to the TDO2 intron and suppresses GR expression; simultaneously, EZH2-mediated H3K27me3 on the TDO2 transposon (L1PA5) blocks GR binding and TDO2 transcription in androgen-sensitive prostate cancer. Here, NR3C1 is linked to prostate cancer.